Help your patients with Primary Periodic Paralysis gain greater symptom control

Trouble viewing this e-mail? Please click here to view in your browser.

Prescribing Information | Important Safety Information

Indication

KEVEYIS is indicated for the treatment of primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and related variants.

Please see Important Safety Information below.

KEVEYIS can help patients gain greater control of PPP symptoms by decreasing the number, severity, and duration of attacks.^1-3

Study Design^1,2: Study 1 was a 9-week, double-blind, placebo-controlled, multicenter study that consisted of 2 substudies: hyperkalemic periodic paralysis (n=21) and hypokalemic periodic paralysis (n=44). The primary endpoint was the average number of self-reported attacks of muscle weakness, per week, the last 8 weeks of the study. A total of 36 adults (18+ years of age) were treated with KEVEYIS across the 2 substudies.

Level I evidence supports KEVEYIS in the long-term management of PPP¹

Find more details on the KEVEYIS clinical trials and results here.

Are there patients suffering from the debilitating effects
of PPP in your practice?

Get them started on KEVEYIS with a
KEVEYIS Start Form

Contact your Area Business Specialist
[First, Last - ABS@strongbridgebio.com]
to schedule a discussion about KEVEYIS.

Important Safety Information

Contraindications

•	Hypersensitivity to dichlorphenamide or other sulfonamides
•	Concomitant use of KEVEYIS and high-dose aspirin
•	Severe pulmonary disease, limiting compensation to metabolic acidosis caused by KEVEYIS
•	Hepatic insufficiency: KEVEYIS may aggravate hepatic encephalopathy

Warnings and Precautions

Hypersensitivity/Anaphylaxis/Idiosyncratic Reactions

•	Fatalities associated with the administration of sulfonamides have occurred due to adverse reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anemia and other blood dyscrasias.
•	Pulmonary involvement can occur in isolation or as part of a systemic reaction.
•	Discontinue KEVEYIS at the first appearance of skin rash or any sign of immune-mediated or idiosyncratic adverse reaction.

Concomitant Use of Aspirin

•	Anorexia, tachypnea, lethargy, and coma have been reported with concomitant use of dichlorphenamide and high-dose aspirin.
•	The concomitant use of KEVEYIS and high-dose aspirin is contraindicated.
•	Use with caution in patients receiving low-dose aspirin.

Hypokalemia

•	KEVEYIS increases potassium excretion and can cause hypokalemia.
•	The risk of hypokalemia is greater when KEVEYIS is used in patients with conditions associated with hypokalemia (eg, adrenocortical insufficiency, hyperchloremic metabolic acidosis, or respiratory acidosis), and in patients receiving other drugs that may cause hypokalemia (eg, loop diuretics, thiazide diuretics, laxatives, antifungals, penicillin, and theophylline).
•	Baseline and periodic measurements of serum potassium are recommended.
•	If hypokalemia develops or persists, consider reducing the dose or discontinuing KEVEYIS.

Metabolic Acidosis

•	KEVEYIS can cause hyperchloremic non–anion gap metabolic acidosis.
•	Concomitant use of KEVEYIS with other drugs that cause metabolic acidosis may increase the severity of metabolic acidosis.
•	Baseline and periodic measurements of serum bicarbonate are recommended.
•	If metabolic acidosis develops or persists, consider reducing the dose or discontinuing KEVEYIS.

Falls

•	KEVEYIS increases the risk of falls; risk is greater in the elderly and with higher doses.
•	Consider dose reduction or discontinuation of KEVEYIS in patients who experience falls while treated with KEVEYIS.

Pregnancy and Lactation

Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known in humans whether dichlorphenamide is excreted in human milk; exercise caution when administered to a nursing woman.

Adverse Reactions

The most common adverse reactions seen in clinical trials (incidence ≥ 10% and greater than placebo) include paresthesias, cognitive disorder, dysgeusia, and confusional state.

Please see Full Prescribing Information.

References: 1. KEVEYIS Prescribing Information. Feasterville-Trevose, PA: Strongbridge Biopharma; 2017. 2. Sansone VA, Burge J, McDermott MP, et al; for the Muscle Study Group. Randomized, placebo-controlled trials of dichlorphenamide in periodic paralysis. Neurology. 2016;86:1408-1416. 3. Tawil R, McDermott MP, Brown R Jr, et al. Randomized trials of dichlorphenamide in the periodic paralyses. Ann Neurol. 2000;47:46-53.

This message was sent by: Strongbridge Biopharma • 900 Northbrook Drive, Suite 200 • Trevose, PA 19053

This message and any attachments are for the designated recipient only and may contain privileged,
proprietary, or otherwise private information. If you have received this in error, please notify the sender
immediately and delete this message. Any other use of this email is prohibited.

Unsubscribe from this list.

www.strongbridgebio.com

KEVEYIS^® is a registered trademark licensed exclusively in the U.S. to Strongbridge Biopharma plc.
STRONGBRIDGE BIOPHARMA^® is a registered trademark of the Strongbridge Biopharma plc. companies,
which include Strongbridge Ireland Limited and Strongbridge U.S. Inc.

KEV-0426 10/2018